Profile
| Metric | Value |
|---|---|
| Full Name | Apogee Therapeutics, Inc. |
| Ticker | NASDAQ: APGE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | apogeetherapeutics.com |
| Employees | 196 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $76.42 | |
| Price, 1D Change | -3.21% | |
| Market Cap | $5B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.24 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$3.30 | |
| EPS, 1Y Change | -99.04% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.30 | |
| EPS Estimate | -$4.19 | |
| EPS Est. Change | -26.83% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $76.42 | |
| Price Target | - | $95.00 |
| Price Tgt. Change | - | +24.32% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.72 | -$1.66 | +39.04% | |
| -$3.09 | -$3.30 | -6.66% | |
| -$4.19 | N/A | -26.83% | |
| -$4.97 | N/A | -50.54% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +55.28% | |
| Price, 3Y | - | |
| Market Cap, 1Y | +78.37% | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -99.04% | |
| EPS, 3Y | -320.34% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $76.42 | |
| SMA 200 | $46.91 | |
| SMA 200 vs Price | -38.62% | |
| SMA 50 | $68.92 | |
| SMA 50 vs Price | -9.80% | |
| Beta | 1.24 | |
| ATR | $3.49 | |
| 14-Day RSI | 67.03 | |
| 10-Day Volatility | 18.34% | |
| 1-Year Volatility | 64.26% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$3.30 | |
| Gross Profit | -$189.00K | |
| - | ||
| Operating Profit | -$216.87M | |
| - | ||
| Net Income | -$182.15M | |
| - | ||
| EBITDA | -$216.68M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| Current Ratio | 18.55 | |
| Quick Ratio | 18.55 | |
| - | ||
| - | ||
| Altman Z-Score | 83.58 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 8.90 | |
| EV/EBITDA | -16.66 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $716.79M | |
| Cash & Equivalents | $141.79M | |
| Total Assets | $753.95M | |
| Current Assets | $529.71M | |
| Total Liabilities | $37.16M | |
| Current Liabilities | $28.56M | |
| Total Debt | $11.83M | |
| Short Term Debt | $3.23M | |
| Accounts Payable | $1.07M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $216.87M | |
| Operating Expenses | $216.87M | |
| Cost Of Goods Sold | $189.00K | |
| SG&A | $49.01M | |
| D&A | $189.00K | |
| Interest Expense | $0.00 | |
| Income Tax | $18.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$171.17M | |
| CFI | -$300.46M | |
| CFF | $495.11M | |
| Capex | $1.15M | |
| Free Cash Flow | -$172.33M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| BTIG | → | |
| Stephens & Co. | ||
| Deutsche Bank | ||
| RBC Capital | → | |
| Craig-Hallum | ||
| Mizuho | ||
| BTIG | → | |
| RBC Capital | ||
| B of A Securities | → | |
| Guggenheim | → |
Analyst sentiment
Institutional ownership
Screeners with APGE
Data Sources & References
- APGE Official Website www.apogeetherapeutics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1974640/000119312525273260/0001193125-25-273260-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1974640/000095017025030385/0000950170-25-030385-index.htm
- APGE Profile on Yahoo Finance finance.yahoo.com/quote/APGE
- APGE Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/apge
FAQ
What is the ticker symbol for Apogee Therapeutics, Inc.?
The ticker symbol for Apogee Therapeutics, Inc. is NASDAQ:APGE
Does Apogee Therapeutics, Inc. pay dividends?
No, Apogee Therapeutics, Inc. does not pay dividends
What sector is Apogee Therapeutics, Inc. in?
Apogee Therapeutics, Inc. is in the Healthcare sector
What industry is Apogee Therapeutics, Inc. in?
Apogee Therapeutics, Inc. is in the Biotechnology industry
What country is Apogee Therapeutics, Inc. based in?
Apogee Therapeutics, Inc. is headquartered in United States
When did Apogee Therapeutics, Inc. go public?
Apogee Therapeutics, Inc. initial public offering (IPO) was on July 14, 2023
Is Apogee Therapeutics, Inc. in the S&P 500?
No, Apogee Therapeutics, Inc. is not included in the S&P 500 index
Is Apogee Therapeutics, Inc. in the NASDAQ 100?
No, Apogee Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Apogee Therapeutics, Inc. in the Dow Jones?
No, Apogee Therapeutics, Inc. is not included in the Dow Jones index
When was Apogee Therapeutics, Inc. last earnings report?
Apogee Therapeutics, Inc.'s most recent earnings report was on November 10, 2025
When does Apogee Therapeutics, Inc. report earnings?
The next expected earnings date for Apogee Therapeutics, Inc. is March 2, 2026